Halozyme Therapeutics (HALO) Goodwill (2022 - 2026)

Halozyme Therapeutics (HALO) has 5 years of Goodwill data on file, last reported at $582.3 million in Q1 2026.

• Goodwill for Q1 2026 came in at $582.3 million, up 39.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $582.3 million (up 39.71% YoY), and the FY2025 annual result was $580.4 million, up 39.23% from the prior year.
• Goodwill was little changed at $582.3 million in Q1 2026 per HALO's latest filing, from $580.4 million in the prior quarter.
• Over five years, Goodwill peaked at $582.3 million in Q1 2026 and troughed at $199.5 million in Q2 2022.
• A 5-year average of $409.7 million and a median of $416.8 million in 2023 frame the typical range for Goodwill.
• The sharpest annual moves came in 2023 and 2024: Goodwill jumped 108.95% in 2023, then changed 0.0% in 2024.
• A 5-year view of Goodwill shows it stood at $409.0 million in 2022, then grew by 1.9% to $416.8 million in 2023, then changed by 0.0% to $416.8 million in 2024, then jumped by 39.23% to $580.4 million in 2025, then climbed by 0.34% to $582.3 million in 2026.
• Business Quant data shows HALO's Goodwill at $582.3 million in Q1 2026, $580.4 million in Q4 2025, and $416.8 million in Q3 2025.